Skip to main content

Company

Cipla

11 published works

  1. Big Molecule Watch

    Cipla and Qilu Announce Exclusive U.S. Licensing and Supply Agreement for Pembrolizumab Biosimilar

    By Sam Herron

    On September 3, 2026, InvaGen Pharmaceuticals Inc., a wholly owned subsidiary of Cipla Limited, announced a strategic partnership and exclusive license with Qilu Pharmaceutical Co., Ltd. for the licensing and…

  2. PTAB Litigation Blog

    Discretionary Denial of IPR Institution Due to Advanced Hatch-Waxman Litigation

    By Matthew Johnson

    Visit Jones Day's PTAB Litigation blog at www.ptablitigationblog.com. By Nicole Prescott,* Phillip Shelton, and Matt Johnson – In a recent decision, the Patent Trial and Appeals Board (“PTAB”) exercised its…

  3. Delaware Intellectual Property Litigation

    Judge Connolly Grants Plaintiffs’ Request to Preclude Defendant from Maintaining Its Invalidity Defense Based on An Undisclosed Inventorship Theory

    By Fox Rothschild LLP

    By Memorandum Order entered by The Honorable Colm F. Connolly in Pharmacyclics LLC et al. v. Cipla Limited, et al., Civil Action No. 18-192-CFC/CJB (D.Del. November 10, 2020) (Consolidated), the…

  4. Big Molecule Watch

    Biosimilars Partnership Updates

    By Big Molecule Watch

    Alvotech and Cipla Medpro, a wholly owned subsidiary of Cipla Limited, recently announced an exclusive partnership “to bring key biosimilars to patients in markets such as South Africa.”  The biosimilars…

  5. Life Science Legal Report

    PTAB Issues Precedential Decision to Clarify 35 U.S.C. § 317(b) Collateral Agreements, and Three Informative Decisions

    By Mark Bailey

    On Thursday, June 11, 2020, the PTAB designated one decision as precedential and three decisions as informative, on issues including: 1) the statutory scope of confidential settlement agreements, 2) design…

  6. Life Science Legal Report

    PTAB Technology Center (TC) 1600 Decision Round-Up: Week of May 21-25, 2018

    By Lara J. Dueppen

    Aside from a quick termination of IPR proceedings pending settlement in Argentum Pharmaceuticals LLC v. Cipla Ltd., No. IPR2017-00807 (Decision Entered May 21, 2018), the Board entered four decisions in…

  7. The Trade Secret Litigator

    Merial Ltd. v. Cipla, Ltd.: Federal Circuit Strikes a Blow Against Jurisdictional Gamesmanship by Foreign Companies in IP Disputes

    By John Marsh

    Merial Ltd. v. Cipla, Ltd.: Federal Circuit Strikes a Blow Against Jurisdictional Gamesmanship by Foreign Companies in IP Disputes

  8. Essential Patent Blog

    Patent Alert: Federal Circuit sustains contempt for violating injunction previously entered as part of default judgment (Merial v. Cipla)

    By Essential Patent Blog

    Today, Thu., May 31, 2012, in Merial v. Cipla, No. 2011-1471, the Federal Circuit (Lourie, Schall (dissent) and Reyna) affirmed entry of contempt for violating an injunction that had been entered…

  9. The Trademark Blog

    Outline of CIPLA Talk

    By Marty Schwimmer

    Issues re Non-US Online Infringement Litigation Domain Name In Rem: Decker v 2011cheapuggs.com, (ED Va Jan 6, 2012) Order. Non-ACPA 'in rem' Chanel v Doe (eukuk.com), 11-cv-01508-KJD-PAL (D Nev) (Chanel…

  10. The Trademark Blog

    Ollie On Trademarks Follow-up: Cipla Settles

    By Marty Schwimmer

    The lawsuit reported by my dog Ollie here is said to be settled here.